A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi
A phase 3 trial of Zilovertamab vedotin, Rituximab, Cyclophosphamide in diffuse large b-cell lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) is a phase 3 interventional study registered as NCT06717347 by Merck Sharp & Dohme LLC, with 1046 participants planned, started 2025-01-27 and due to reach its primary completion in 2029-07-02. Interventions recorded: Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Shares Zilovertamab vedotin, Prednisone, Rituximab, Cyclophosphamide.
- TrialA Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Shares Zilovertamab vedotin, Prednisone, Rituximab, Cyclophosphamide.
- TrialA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Shares Prednisone, Vincristine, Rituximab, Cyclophosphamide.
- TrialA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa
Shares Prednisone, Vincristine, Rituximab, Cyclophosphamide.
- TrialSafety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Shares Prednisone, Vincristine, Rituximab, Cyclophosphamide.
- TrialTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Shares Prednisone, Vincristine, Rituximab, Cyclophosphamide.
- TrialA Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Shares Prednisone, Vincristine, Rituximab, Cyclophosphamide.
- TrialA Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy
Shares Prednisone, Vincristine, Rituximab, Cyclophosphamide.